(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

The growing prevalence of ultrahigh-cost drugs under development is prompting health systems nationwide to rethink strategies ...

Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

CARGO Therapeutics slashes workforce, halts drug development after a failed trial, with plans for a potential reverse merger.

Pharmaceutical consultants apply their comprehensive expertise in different areas to accelerate the drug development process.

The future of American drug innovation is threatened by US regulations that permit knockoff versions of new drugs to be sold ...

Amid the ethical and legal arguments, a fundamental question remains: How much do we truly understand about the drugs used in ...